Centrexion Therapeutics announced completion of patient enrollment ahead of schedule in its pivotal Phase 3 VICTORY-1 trial, a randomized, double-blind, placebo-controlled, 325-patient, 52-week clinical trial to evaluate the safety and efficacy of a single intra-articular injection of CNTX-4975 in subjects with chronic moderate-to-severe knee osteoarthritis pain. Topline results from VICTORY-1 are expected to be reported in the first quarter of 2020.
The Committee discusses the assessment of opioid analgesic sparing outcomes in clinical trials of acute pain and will be asked to comment on the trial design and endpoints of these studies and how to determine the clinical relevance of the results. Companies participating include Pacira Pharmaceuticals, Centrexion Therapeutics and Flexion Therapeutics in the discussion being held at the FDA Silver Spring, MD offices on November 15 at 8 am. Webcast Link